| Literature DB >> 35911357 |
Abstract
The West Nile virus (WNV) belongs to the genus of flaviviruses and is known to cause irreversible neurologic deficits. Neuroinvasive WNV cases continue to be rare and have a higher prevalence in South America, Africa, and Asia. Here we report a 55-year-old female from North America who presented with acute-onset encephalopathy, fever, myalgias, and Anton syndrome. Neuroradiographic findings included diffuse white matter abnormalities of both cortical and subcortical structures and the patient was diagnosed with posterior reversible encephalopathy syndrome (PRES). Further workup revealed WNV antibodies in both cerebrospinal fluid (CSF) and serum. Management of WNV encephalitis continues to be poor and thus the patient was referred to a long-term care facility. Furthermore, Anton syndrome is a rare focal neurologic deficit that has never been previously associated with the WNV. This case aims to highlight the epidemiology of WNV in the United States, the mechanisms of WNV encephalitis, and an overview of Anton syndrome.Entities:
Keywords: anton's syndrome; anton–babinski syndrome; flavivirus; infectious disease; internal medicine; leukoencephalopathy; neuroinfectious disease; neuroinvasive west nile virus; neurology; west nile virus
Year: 2022 PMID: 35911357 PMCID: PMC9312882 DOI: 10.7759/cureus.26264
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1MRI brain T2-fluid attenuated inversion recovery (FLAIR) axial view obtained on patient admission
A-B: significant T2-hyperintensities in both bilateral frontoparietal and occipital cortices; C-D: Significant T2-hyperintensities in subcortical structures
Figure 2MRI brain T2-fluid attenuated inversion recovery (FLAIR) axial view obtained during week seven of the admission
A-B: Chronic evolution of T2-hyperintensities in both bilateral frontoparietal and occipital cortices; C-D: Chronic evolution of T2-hyperintensities in subcortical structures
Cerebrospinal fluid (CSF) and serum studies obtained during the seventh week of the admission
CSF: Cerebrospinal fluid; RBC: Red blood cell; WBC: White blood cell; VDRL: Venereal Disease Research Laboratory; WNV; West Nile virus; IgG: Immunoglobulin G; IgA; Immunoglobulin A; IgM; Immunoglobulin M; Ab: Antibody; DNA: Deoxyribonucleic acid; JCV: John Cunningham virus; PCR: Polymerase chain reaction; ANCA: Antineutrophil cytoplasmic antibody; ANA: Anti nuclear antibody; RT-QuIC: Real-time quaking-induced conversion; AMPAR1: AMPAR Receptor 1; AMPAR2: AMPAR Receptor 2; ANNA1: Type 1 antineuronal nuclear antibody; ANNA2: Type 2 antineuronal nuclear antibody; ANNA3: Type 3 antineuronal nuclear antibody; CASPR-2: Contactin-associated protein-like 2; CRMP5: Collapsin response-mediator protein-5; DPPX: Dipeptidyl peptidase-like protein 6; GABA-B: Gamma-aminobutyric acid-B; GAD65: Glutamic acid decarboxylase 65; LGI-1: Leucine-rich glioma-inactivated protein 1; NMDAR: N-methyl-D-aspartate receptor; PCA-Tr: Purkinje Cell cytoplasmic antibody type Tr; PCA1: Purkinje Cell cytoplasmic antibody type 1; VGCC: Voltage-gated calcium channel; VGKC: Voltage-gated potassium channel; RNA: ribonucleic acid
| Lab Parameter | Numerical value with units and reference range |
| Glucose, CSF | 85 mg/dL (50-80) |
| Protein, CSF | 97 mg/dL (15-45) |
| RBC, CSF | 3 (0) |
| Appearance, CSF | Clear |
| WBC, CSF | 0 |
| VDRL, CSF | Non-reactive |
| Lymphocytes %, CSF | 80% |
| Mono/Macrophage %, CSF | 20% |
| Total Cells Counted, CSF | 5 |
| IgG, CSF | 6.2 mg/dL (0.0-6.0) |
| Albumin, CSF | 45 mg/dL (0-35) |
| Albumin Nephelometry | 2553 mg/dL (3500-5200) |
| Albumin Index | 17.6 (0.0-9.0) |
| IgG Index | 0.57 (0.28-0.66) |
| CSF IgG/Albumin Ratio | 0.20 (0.09-0.25) |
| CSF Oligoclonal Bands | Negative |
| CSF IgG Synthesis Rate | 6.8 |
| Herpes Simplex 1 PCR, CSF | Non-reactive |
| Herpes Simplex 2 PCR, SF | Non-reactive |
|
| Non-reactive |
|
| Non-reactive |
|
| Non-reactive |
|
| Non-reactive |
| Cytomegalovirus DNA, CSF | Non-reactive |
| Enterovirus DNA, CSF | Non-reactive |
| Human Herpes Virus 6 DNA, CSF | Non-reactive |
| Human parechoviruses DNA, CSF | Non-reactive |
|
| Non-reactive |
| JCV Quantitative PCR, CSF | Non-reactive |
| ANCA | Negative |
| Mitochondrial Ab | Negative |
| Thyroglobulin Ab | 7 (<10) |
| ANA Titer | <1:40 (<1:40) |
| Proteinase-3 Ab | < 1.0 (<1.0) |
| Thyroid Peroxidase Ab | 1 IU/mL (<9) |
| 14-3-3 Protein Tau, Total, CSF | Negative |
| RT-QuIC, CSF | Negative |
| WNV, IgG Ab, CSF | 1.89 (<1.30) |
| WNV IgM Ab, CSF | 1.10 (<1.30) |
| WNV IgG Ab, Serum | 2.89 (<2.62) |
| WNV IgM Ab, Serum | <1.10 (<1.10) |
| WNV Ab Neutralization Confirmatory Test | Positive |
| St. Louis Encephalitis IgG Ab, CSF | <1:10 (<1:10) |
| St. Louis Encephalitis IgM Ab, CSF | <1:10 (<1:10) |
| St. Louis Encephalitis IgG Ab, Serum | <1:10 (<1:10) |
| St. Louis Encephalitis IgM Ab, Serum | <1:10 (<1:10) |
| Japanese Encephalitis IgG Ab, CSF | <1:10 (<1:10) |
| Japanese Encephalitis IgM Ab, CSF | <1:10 (<1:10) |
| Japanese Encephalitis IgG Ab, Serum | <1:10 (<1:10) |
| Japanese Encephalitis IgM Ab, Serum | <1:10 (<1:10) |
| Powassan Virus IgG Ab, CSF | <1:10 (<1:10) |
| Powassan Virus IgM Ab, CSF | <1:10 (<1:10) |
| Powassan Virus IgG Ab, Serum | <1:10 (<1:10) |
| Powassan Virus IgG Ab, Serum | <1:10 (<1:10) |
| SARS-CoV-2 RNA PCR, CSF | Negative |
| Vitamin A | 81 mcg/dL |
| Acetylcholine Receptor Ganglionic Ab | <53 (<53) |
| Anti-SOX 1 Ab | <11 (<11) |
| AMPAR1 Ab | Negative |
| AMPAR2 Ab | Negative |
| Antiphysin Ab | <11 (<11) |
| ANNA1 Ab | <11 (<11) |
| ANNA2 Ab | <11 (<11) |
| ANNA3 Ab | Negative |
| Aquaporin 4 Ab | Negative |
| CASPR-2 Ab | Negative |
| CV2/CRMP5 Ab | <11 (<11) |
| DPPX Receptor Ab | Negative |
| Epstein Barr Virus DNA, Quantitative | Not detected |
| GABA-B Receptor Ab | <11 (<11) |
| GAD65 Ab | <11 (<11) |
| LGI -1 Ab | Negative |
| Ma2/Ta Ab | <11 (<11) |
| Myelin Ab | Negative |
| NMDAR Ab | Negative |
| PCA-Tr Ab | Negative |
| PCA1 Ab | <11 (<11) |
| VGCC Type N Ab | <55 (<55) |
| VGKC Protein Complex, Ab | <50 pmol/L (<50) |
| VGCC Protein Complex Ab | <30 pmol/L (<30) |
| Zinc Protein 4 Ab | <11 (<11) |
| Titin Ab | <11 (<11) |
| Phosphatidylserine IgA | <20 (<20) |
| Phosphatidylserine IgM | <10 (<10) |
| Phosphatidylserine IgG | <15 (<15) |
| Recoverin Ab | <11 (<11) |
| Striated Muscle Ab | Negative |
Figure 3Map of the United States depicting the geographical distribution of West Nile virus (WNV) human disease cases in 2021
Source: https://wwwn.cdc.gov/arbonet/maps/ADB_Diseases_Map/index.html
Barrier systems within the central nervous system (CNS)
BBB: Blood-brain barrier; CSF: Cerebrospinal fluid
| Unit | Restricting Factor | Components | Location |
| BBB | Endothelial cell – tight junctions | Astrocyte end-feet, pericytes, capillary basement membrane. | Cerebral blood vessels |
| Blood-CSF Barrier (Choroid Plexus) | Epithelial cell and tanycyte – tight junctions | Astrocyte end-feet, microglial cells | Choroid plexus and circumventricular organs |
| Brain-CSF Barrier (Pia) | Endothelial-cell tight junctions | Astrocyte end-feet, fenestrated dural vessels | Pia mater (pial blood vessels) |
| CSF-Brain Barrier (Embryonic) | Ependymal cells – strap junctions (Ventricular lining) | Radial glial cells, neuroepithelial cells | Ventricular system |
Figure 4Proposed mechanisms of West Nile virus (WNV)-mediated encephalitis
BBB: Blood-brain barrier; IL-6: Interleukin-6; TNF-α; Tumor necrosis factor-α; TLR-3: Toll like receptor-3
Figure 5Normal visual circuitry compared to bilateral visual cortex lesion associated with Anton syndrome